GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Active Biotech AB (LTS:0GQU) » Definitions » Debt-to-Revenue

Active Biotech AB (LTS:0GQU) Debt-to-Revenue : N/A (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Active Biotech AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Active Biotech AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Active Biotech AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Active Biotech AB's annualized Revenue for the quarter that ended in Mar. 2024 was kr0.00 Mil.


Active Biotech AB Debt-to-Revenue Historical Data

The historical data trend for Active Biotech AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Active Biotech AB Debt-to-Revenue Chart

Active Biotech AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.92 0.30 N/A N/A N/A

Active Biotech AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Active Biotech AB's Debt-to-Revenue

For the Biotechnology subindustry, Active Biotech AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Active Biotech AB's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Active Biotech AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Active Biotech AB's Debt-to-Revenue falls into.



Active Biotech AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Active Biotech AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.545 + 3) / N/A
=N/A

Active Biotech AB's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Active Biotech AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Active Biotech AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Active Biotech AB (LTS:0GQU) Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, 223 63
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy.

Active Biotech AB (LTS:0GQU) Headlines

No Headlines